Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience
- PMID: 18443881
- DOI: 10.1245/s10434-008-9933-y
Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience
Abstract
Background: Intrahepatic cholangiocarcinoma (ICC) is an unusual tumour.
Methods: The clinicopathological data of 67 patients with ICC and combined hepatocellular-cholangiocarcinoma (HCC-ICC) are presented.
Results: HCV-HBV infection was present in 37.3% and chronic liver disease in 38.7% of cases, a rate higher than in the normal population; in these patients the cancer was small, often asymptomatic and of combined type. Liver resection was performed in 51 patients; at 1, 3 and 5 years, overall survival was 87.9%, 59.0%, and disease-free survival was 47.7% and 78.8%, 51.4%, and 46.7%, respectively. The better results were in the group of cirrhotic patients in whom ICC was diagnosed by a screening program for HCC (5-year survival 76.6%). Nodal metastasis showed negative prognostic value for both overall and disease-free survival; in N+ patients mean survival was 14.7 months after liver resection and lymph node dissection.
Conclusion: Viral infection and cirrhosis may be considered risk conditions for ICC and combined HCC-ICC; in resected patients survival was good. Nodal metastases must not be considered a contraindication for liver resection.
Similar articles
-
Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.Ann Surg Oncol. 2009 Mar;16(3):623-9. doi: 10.1245/s10434-008-0278-3. Epub 2009 Jan 6. Ann Surg Oncol. 2009. PMID: 19130133
-
Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27. Ann Surg Oncol. 2012. PMID: 22451237
-
Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.Hepatobiliary Pancreat Dis Int. 2007 Apr;6(2):161-5. Hepatobiliary Pancreat Dis Int. 2007. PMID: 17374575
-
[Hepatocellular carcinoma and cholangiocarcinoma--different prognosis, pathogenesis and therapy].Zentralbl Chir. 2007 Aug;132(4):300-5. doi: 10.1055/s-2007-981195. Zentralbl Chir. 2007. PMID: 17724632 Review. German.
-
Intrahepatic cholangiocarcinoma: new insights in pathology.Semin Liver Dis. 2011 Feb;31(1):49-60. doi: 10.1055/s-0031-1272839. Epub 2011 Feb 22. Semin Liver Dis. 2011. PMID: 21344350 Review.
Cited by
-
Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update.Cancers (Basel). 2023 Jan 13;15(2):494. doi: 10.3390/cancers15020494. Cancers (Basel). 2023. PMID: 36672443 Free PMC article. Review.
-
Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.World J Gastroenterol. 2014 Sep 21;20(35):12615-20. doi: 10.3748/wjg.v20.i35.12615. World J Gastroenterol. 2014. PMID: 25253966 Free PMC article.
-
A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma.Curr Hepatol Rep. 2020 Dec;19(4):478-485. doi: 10.1007/s11901-020-00556-4. Epub 2020 Oct 31. Curr Hepatol Rep. 2020. PMID: 33415066 Free PMC article.
-
Surgical outcomes of intrahepatic cholangiocarcinoma.Surg Today. 2011 Jul;41(7):896-902. doi: 10.1007/s00595-011-4517-z. Epub 2011 Jul 12. Surg Today. 2011. PMID: 21748603 Review.
-
Cholangiocarcinoma and liver transplantation: What we know so far?World J Gastrointest Pathophysiol. 2021 Sep 22;12(5):84-105. doi: 10.4291/wjgp.v12.i5.84. World J Gastrointest Pathophysiol. 2021. PMID: 34676129 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical